Alosetron NDC 70756-701

NDC codes

FDA NDC Directory

Product NDC (as listed)70756-701Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70756-0701Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70756-701-30	70756070130	30 TABLET in 1 BOTTLE (70756-701-30)Marketed from Sep 14, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alosetron
Generic name (nonproprietary): alosetron
Active ingredients: Alosetron hydrochloride — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lifestar Pharma LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213614
Marketing start: Sep 14, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Serotonin 3 Receptor Antagonists (Mechanism)
Identifiers: Product ID 70756-701_6e1e5a99-5018-42e7-8e2c-bcd0ac1e80fbSPL ID 6e1e5a99-5018-42e7-8e2c-bcd0ac1e80fbSPL set ID 2846a244-7540-442b-81bc-638e641497ceRxCUI 259306, 403975UNII 2F5R1A46YW
Pharmacologic class: Serotonin-3 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470756070130 followed by a unit qualifier and the quantity

Package 70756-0701-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 1, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with alosetron tablets, the indication is restricted to th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213614

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213614
Product	Strength	Form · route	Labeler	Product NDC
Alosetron	Alosetron hydrochloride .5 mg/1	TabletOral	Lifestar Pharma LLC	70756-702
Alosetron	Alosetron hydrochloride .5 mg/1	TabletOral	Bryant Ranch Prepack	63629-2517
Alosetron	Alosetron hydrochloride 1 mg/1	TabletOral	Bryant Ranch Prepack	63629-2518